The standard baseline panel for Wegovy patients includes:

• Comprehensive metabolic panel (CMP): Covers fasting glucose, kidney markers (creatinine, BUN, eGFR), liver enzymes (ALT, AST), and electrolytes
• Hemoglobin A1c: A critical marker for blood sugar trends, even for patients who have not been diagnosed with diabetes
• Lipid panel: Baseline cholesterol and triglyceride levels, which often improve significantly with weight loss
• TSH: Thyroid function screening, relevant because semaglutide's prescribing information includes a boxed warning about thyroid C-cell tumors observed in rodent studies
• CBC: General health marker that can identify anemia, infection, or other blood-related concerns

Your physician may add other tests based on your health history, such as fasting insulin, vitamin D, or inflammatory markers like CRP.

Wegovy delivers semaglutide at 2.4 mg weekly, which is the highest approved dose of semaglutide. This higher dose produces more weight loss but also more pronounced physiological effects:

• Greater blood sugar reduction: Even non-diabetic patients may see significant glucose changes, and patients on diabetes medications need dose adjustments to avoid hypoglycemia
• More intense GI effects: Higher doses of semaglutide cause more nausea, vomiting, and diarrhea, which can lead to dehydration and stress on the kidneys
• Faster weight loss: Rapid weight loss can affect gallbladder function and increase the risk of gallstones, which may show up in lab work through elevated liver or gallbladder markers

Monitoring these parameters helps your physician stay ahead of potential complications and adjust your treatment as needed.

A standard monitoring timeline for Wegovy patients:

1. Before treatment: Full baseline panel
2. At 3 months: CMP and A1c to assess early response and kidney health
3. At 6 months: Comprehensive panel including lipids to document metabolic improvements
4. Every 6 to 12 months: Routine follow-up labs on an ongoing basis
5. As needed: Additional labs if new symptoms arise, if you experience significant dehydration, or if your medication regimen changes

This schedule is flexible. Your FormBlends physician may recommend more or less frequent testing depending on your health status and how you respond to treatment. Wegovy

Follow-up blood work frequently shows positive changes that go far beyond what the scale measures:

• A1c reduction: Many patients see their A1c drop by 0.5 to 1.5 points, sometimes moving out of the prediabetic range entirely
• Improved cholesterol: LDL and triglycerides often decrease, while HDL may increase
• Better liver health: Patients with non-alcoholic fatty liver disease frequently see liver enzyme levels normalize
• Lower inflammation: Markers like CRP (if measured) tend to improve with weight loss
• Improved kidney markers: Weight loss reduces the metabolic burden on the kidneys

These measurable improvements are a powerful reminder that weight loss with Wegovy is about more than appearance. It is about transforming your overall health.

Technically, there is no absolute legal requirement for blood work before every Wegovy prescription. Some providers may prescribe based on health history alone. However, this approach has significant limitations.

Without baseline labs, your provider cannot:

• Detect undiagnosed conditions like diabetes, thyroid disease, or kidney impairment
• Identify contraindications that make semaglutide unsafe for you
• Objectively measure your metabolic improvements over time
• Make informed dose adjustments based on clinical data

At FormBlends, we view lab work as a cornerstone of quality care, not an optional add-on. It protects you and gives your physician the information needed to optimize your results.

Kidney function monitoring deserves special attention for Wegovy patients. The GI side effects of semaglutide (nausea, vomiting, diarrhea) can cause dehydration, which puts stress on the kidneys. Cases of acute kidney injury have been reported in patients taking GLP-1 medications, primarily linked to dehydration.

Key kidney markers to watch include:

• Creatinine: A waste product filtered by the kidneys; rising levels may indicate reduced kidney function
• BUN (blood urea nitrogen): Another marker of kidney filtration
• eGFR (estimated glomerular filtration rate): The most comprehensive measure of kidney function

Staying well-hydrated is one of the most important things you can do while taking Wegovy. If you experience persistent vomiting or diarrhea, contact your physician promptly.